Stress Model for Antidepressant Drug Discovery
Stress is a major environmental risk factor that triggers depressive episodes, inducing symptoms such as anhedonia, negative cognitive bias, and...
Continue Reading
Stress is a major environmental risk factor that triggers depressive episodes, inducing symptoms such as anhedonia, negative cognitive bias, and...
Continue Reading
Oligonucleotide therapeutics represent a transformative treatment modality with demonstrated potential across metabolic disorders, CNS diseases, muscular dystrophies, and a broad...
Continue Reading
Cognitive dysfunction affects over 50 million individuals worldwide, with Alzheimer’s disease (AD) representing two-thirds of cases. Due to the complexity...
Continue Reading
Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...
Continue Reading
Evidence suggests that type 2 diabetes mellitus (T2DM) is associated with cognitive dysfunction and an increased risk of developing neurocognitive...
Continue Reading
Epilepsy is one of the most common neurological disorders, and cell therapy is a promising area of research that has...
Continue Reading
Psychotropic drug abuse, particularly involving amphetamines and ketamine, has been shown to induce alterations in dopaminergic innervation, neuronal structure, and...
Continue Reading
OncoWuXi Express will continue to keep you informed about updates to our online pharmacology model database (OncoWuXi Database), as well...
Continue Reading
Introduction: OncoWuXi Express will continue to keep you informed about updates to our online pharmacology model database (OncoWuXi Database), as...
Continue Reading